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a  b  s  t  r  a  c  t
Avian  inﬂuenza  A  (H7N9),  emerged  in  China  in April  2013,  sparking  fears  of a new,  highly  pathogenic,
inﬂuenza  pandemic.  In addition,  avian  inﬂuenza  A  (H5N1)  continues  to circulate  and remains  a  threat.
Currently,  inﬂuenza  H7N9  vaccines  are  being  tested to be stockpiled  along  with  H5N1  vaccines.  These
vaccines  require  two  doses,  21  days  apart,  for maximal  protection.  We  developed  a mathematical  model
to evaluate  two possible  strategies  for  allocating  limited  vaccine  supplies:  a one-dose  strategy,  where  a
larger number  of people  are  vaccinated  with  a single  dose,  or a  two-dose  strategy,  where  half  as  many
people  are vaccinated  with  two doses.  We  prove  that  there  is  a threshold  in the  level  of protectionnﬂuenza vaccine
athematical model
nfectious disease modeling
obtained  after  the  ﬁrst  dose,  below  which  vaccinating  with  two doses  results  in a  lower  illness attack
rate  than  with  the  one-dose  strategy;  but  above  the  threshold,  the  one-dose  strategy  would  be better.
For  reactive  vaccination,  we show  that  the  optimal  use of  vaccine  depends  on  several  parameters,  with
the  most  important  one  being  the  level  of  protection  obtained  after  the  ﬁrst dose.  We  describe  how  these
vaccine  dosing  strategies  can  be integrated  into  effective  pandemic  control  plans.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
On April 1st 2013, the ﬁrst cases of human infection with
nﬂuenza A (H7N9) were reported in China (WHO, 2013). As of
ovember 17th, 2014, over 450 cases have been reported (CIDRAP,
014a), with an estimated 30% mortality rate (CIDRAP, 2014b).
tudies have shown that this strain may  be better adapted to
ammalian hosts than other avian strains (Xu et al., 2013; Chan
t al., 2013), raising a global concern that inﬂuenza A (H7N9) could
cquire the ability to transmit from person to person triggering
 new inﬂuenza pandemic (Uyeki and Cox, 2013). In response to
his threat, several candidate vaccines are currently being tested,
ith most of them requiring two doses: a prime and a boost three
eeks later (CIDRAP, 2013; WHO, 2013). With new cases arising
ontinuously (WHO, 2014), avian inﬂuenza A (H5N1) remains a
hreat (Linster et al., 2014). Vaccination remains the most effective
∗ Corresponding author. Tel.: +1 206 667 7006; fax: +1 206 667 4378.
E-mail address: laurama@fredhutch.org (L. Matrajt).
ttp://dx.doi.org/10.1016/j.epidem.2015.06.001
755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).intervention against pandemic inﬂuenza, but in the event of a pan-
demic, vaccine will likely be in short supply (Osterholm et al., 2013).
We developed a mathematical model to evaluate two possi-
ble strategies for allocating limited vaccine supplies: a one-dose
strategy, where more people are vaccinated with a single dose
of vaccine, or a two-dose strategy, where half as many people
are vaccinated with the full, required, two  doses. We  consid-
ered both pre-pandemic vaccination and reactive vaccination. For
pre-pandemic vaccination, we  demonstrated that under certain
conditions, there is a threshold in the primary response level
(deﬁned as the percentage of the full vaccine efﬁcacy that will be
reached after the ﬁrst dose), below which the two-dose strategy is
better, but above which vaccinating the most people with a single
dose would yield lower attack rates. We  analyzed different param-
eters affecting the course of an epidemic to determine which ones
carry the most weight in favoring a one-dose versus a two-dose
strategy: initiation of vaccination with respect to the start of the
epidemic, primary response level, vaccination coverage, the kinet-
ics of the vaccine efﬁcacies post-vaccination as functions of time,
and transmissibility of the virus, measured through the basic repro-
duction number, R0 (deﬁned as the expected number of secondary
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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nfections resulting from a single typical infectious person in a com-
letely susceptible population).
For each parameter set, we found a threshold in the value of R0,
elow which the strategy of fewer vaccinees with two  doses results
n a smaller ﬁnal illness attack rate (deﬁned as the percentage of the
opulation who become infected and ill) than the strategy of more
accines with one dose. Above this threshold, our model predicts
hat vaccinating more people with one dose is better. Though the
hreshold depends on all the parameters considered, the primary
esponse level is the most important. Because a vaccine shortage
s very likely to occur for pandemic inﬂuenza, our results could
rovide valuable insights for allocating limited resources.
. Methods
We  used a classic susceptible–infected–removed (SIR) differ-
ntial equations model to simulate an inﬂuenza epidemic in a
omogeneous population. Brieﬂy, the population is partitioned into
hose who are susceptible unvaccinated or vaccinated, infectious
nvaccinated or vaccinated, asymptomatic or symptomatic, and
ecovered. A fraction of those infected will develop symptoms,
hile the rest remain asymptomatic. Infected asymptomatic peo-
le are less infectious than those who are symptomatic. Fig. 1A
hows a schematic diagram of the model.
Vaccine is assumed to be “leaky” (Halloran et al., 1989), that
s, vaccine confers partial protection to all vaccinees. The effect of
accination in an individual is modeled following Halloran et al.
1997) in which vaccine protection has three possible components:
irst, vaccinated individuals have a reduced probability of becom-
ng infected (vaccine efﬁcacy on susceptibility, VES). Then, once
nfected, a vaccinated individual has a reduction in his/her infec-
iousness (vaccine efﬁcacy to reduce infectiousness given infection,
EI), and a reduction in the probability of developing symptoms
vaccine efﬁcacy to prevent or diminish symptoms VEP).
During the ﬁrst two weeks after the ﬁrst dose, the vaccine efﬁca-
ies increase until they reach their primary response level, r1, deﬁned
s the percentage of the overall maximum efﬁcacy obtained after
he full recommended two doses. For example, a primary response
evel of 50% corresponds to obtaining half of the protection after
ne dose, and full protection after two doses.
We  further assumed that it would take only one week for the
econd dose to reach its full efﬁcacy, and that the vaccine efﬁcacy
omponents would remain constant during the third week before
he second dose.
Little is known about the pharmacodynamics of inﬂuenza vac-
ines and their interplay with the immune response. Since we were
nterested in investigating the impact of the shape and the speed
f the vaccine efﬁcacy kinetics on the population-level attack rates
f the one- and two-dose strategies, we modeled vaccine efﬁcacy
uilding up over time and constructed, for each vaccine efﬁcacy
omponent, a family of functions that allows us to change these
eatures. A concave shape corresponds to a vaccine in which pro-
ection is acquired mostly during the ﬁrst few days after vaccination
nd then levels off. A convex shape corresponds to a vaccine efﬁ-
acy in which protection takes a few days to kick in, then grows
xponentially, ﬁnally leveling off during the last few days (Fig. 1B).
he full description of the model, its equations, and the parameters
alues used here are presented in the Appendix. In the text below,
he values of VES, VEI, and VEP always refer to the vaccine efﬁcacy
alues obtained after the second dose of vaccine.
We analyzed vaccination under two different settings: pre-
andemic vaccination in which vaccination occurs well before
he epidemic starts, and reactive vaccination in which vaccination
ccurs after the epidemic has started. We  considered vaccinating
0% of the population with a single dose of vaccine or 25% of thes 13 (2015) 17–27
population with two  doses. A sensitivity analysis showed that our
conclusions do not depend on the population coverage (Supple-
mental material).
3. Results
3.1. Prepandemic vaccination
In this section we assume that vaccination occurred before the
beginning of the epidemic, so that vaccinated people have acquired
all the protection given by a vaccine before the epidemic starts.
This scenario allows us to mathematically analyze the model in full
detail.
Here, we considered a variety of vaccines with different char-
acteristics. First, assume a vaccine reducing susceptibility only (so
that VES > 0 but VEI = 0 = VEP). This is the most common perception
of how a vaccine works. We  analytically demonstrated that for this
model, there is a threshold in the primary response level, r∗1 > 0.5,
that depends on the other parameters, at which the two strate-
gies are equivalent. If r1 < r∗1, then the two dose strategy is always
better, but, if r1 > r∗1 vaccinating twice as many people with one
dose would result in lower attack rates (Fig. 2A and Theorem 1,
Appendix).
Then, suppose that we  have a vaccine that reduces either infec-
tiousness only (so that VEI > 0 but VES = 0 = VEP) or pathogenicity
only (so that VEP > 0 but VEI = 0 = VES). In both cases, we analyti-
cally proved that the threshold r∗1 in the primary response level is
exactly 50%, and that this threshold is independent of all the other
parameters of the model (Fig. 2B and C, and Theorems 2 and 3,
Appendix).
Finally, using numerical simulations, we  studied prepandemic
vaccination when the three vaccine efﬁcacy components can take
any non-negative value. We considered four different vaccines: a
low-efﬁcacy vaccine (VES = 15%, VEI = 0%, and VEP = 24%), a medium-
efﬁcacy vaccine (VES = 40%, VEI = 22.5%, and VEP = 62%), a vaccine
as efﬁcacious as a seasonal vaccine (VES = 40%, VEI = 45%, and
VEP = 75%), and a high-efﬁcacy vaccine (VES = 66%, VEI = 45%, and
VEP = 100%). These values were taken from Basta et al.,  where the
authors used challenge and community-based study data to esti-
mate seasonal inﬂuenza vaccine efﬁcacy (Basta et al., 2008). When
r1 = 30%, for all the vaccines considered, the two-dose strategy was
better with a maximum absolute difference of 6% in the attack rate
(for R0 = 1.4 and the medium-efﬁcacy vaccine, Fig. 3A). For r1 = 50%
and r1 = 70% and for all these vaccines, our simulations suggested
that vaccinating with a single dose would be better than vaccinating
half as many people with two  doses. This difference was accentu-
ated with more efﬁcacious vaccines, with the highest difference
seen for the high-efﬁcacy vaccine when R0 = 1.5 and r1 = 50% (10%
difference in the attack rate, Fig. 3B); and for R0 = 1.6 for r1 = 70%
(16% difference in the attack rate), Fig. 3C.
3.2. Reactive vaccination
Next, we  considered the situation in which vaccination is pro-
vided after the epidemic has started by solving the differential
equations numerically. We  assumed that the three components of
vaccine efﬁcacy are non-negative, and that they all reach the same
primary response level after a single dose of vaccine. We considered
vaccination taking place 45, 60, 75, or 90 days after the epidemic
has started (Fig. S1). We  also considered a model in which vaccina-
tion campaigns are stretched over 10, 20 or 30 days, and showed
that our results are robust to this change (Sensitivity Analysis, Figs.
S2–S6).
Our results suggested that there is a threshold R*, in the basic
reproduction number, above which priming a large number of
L. Matrajt et al. / Epidemics 13 (2015) 17–27 19
Fig. 1. (A) SIR model for inﬂuenza with vaccination with a leaky vaccine. Compartments: N total susceptible population; S0 susceptible unvaccinated individuals; S1 suscep-
tible  vaccinated individuals; I00 infected unvaccinated asymptomatic individuals; I01 infected unvaccinated symptomatic individuals; I10 infected vaccinated asymptomatic
individuals; I11 infected vaccinated symptomatic individuals; Rec00 recovered unvaccinated asymptomatic individuals; Rec01 recovered unvaccinated symptomatic individ-
uals;  Rec10 recovered vaccinated asymptomatic individuals; Rec11 recovered vaccinated symptomatic individuals. See methods for detailed description and equations and
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table 1 for parameter deﬁnitions and values. (B) Vaccine efﬁcacy modeled as a func
inetics of the vaccine efﬁcacies post-vaccination. Vaccine is administered at day 0
eople would result in lower attack rates but below which vaccinat-
ng half as many with the full recommended two doses would result
n fewer symptomatic infections. This threshold R* depends on key
arameters, with the primary response level being the most impor-
ant one. For example, if the primary response level was  20% and the
accine was as efﬁcacious as a seasonal vaccine, then R* = 1.8 but if
he primary response level was 30%, then R* = 1.7 (Fig. 4). Choosing
he wrong policy could result in important differences in the attack
ates: If the primary response level was 20% and R0 = 1.4, then vacci-
ating 50% of the population with a single dose of a seasonal vaccine
ould result in a 13% higher attack rate than vaccinating 25% of
he population with two doses (Fig. 4A). However, if the primary
esponse level was 50% and R0 = 1.8, then vaccinating the same per-
entage of the population with a single dose would result in a 9%
ower attack rate than vaccinating half as many people with two
oses. As expected, difference in the attack rates is more impor-
ant with vaccines that are more efﬁcacious. Fig. 5 represents thef time post-vaccination. We used a one-parameter family of functions to model the
t day 21. See Section 2 for a full description.
contour lines of the absolute difference between the attack rates
of the two-dose and one-dose strategies, with 50% of the population
vaccinated with a single dose and vaccination on day 45 after the
beginning of the epidemic. For small values of R0, (1 ≤ R0 ≤ 1.3), or
for big values of R0 and low values of the primary response level
r1 (0≤  r1 ≤ 20 %), the absolute difference in the attack rates is mini-
mal. This is expected, both strategies will perform well at the lower
end of R0 and poorly at the higher end. The highest absolute differ-
ence is seen for intermediate values of R0. For these values, a very
low primary response level favors the two-dose strategy as little is
gain with a single dose of vaccine, and a very high primary response
level favors the one-dose strategy as most of the protection would
be obtained after the ﬁrst dose. The contour line where both strate-
gies agree is shown in green. Interestingly, for this particular set of
parameters, the strategies yield identical attack rates for primary
response levels much below 50%, with most of the plane favoring
the one-dose strategy (sensitivity analysis showed that this is true
20 L. Matrajt et al. / Epidemics 13 (2015) 17–27
Fig. 2. Attack rates for pre-pandemic vaccination when the vaccine is efﬁcacious (A) against susceptibility only; (B) in reducing infectiousness given infection only; (C) in
reducing pathogenicity only. Solid lines indicate the ﬁnal attack rate when vaccinating 50% of the population with a single dose, dashed lines indicate the ﬁnal attack rates
when  vaccinating 25% of the population with two doses. The colors indicate the vaccine efﬁcacy reached after the second dose.
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lig. 3. Prepandemic vaccination when the primary response is set to (A) 30%; (B) 50
f  the population with two doses, and four different vaccines: a low-efﬁcacy vacci
nd  VEP = 62%), a vaccine as efﬁcacious as a seasonal vaccine (VES = 40%, VEI = 45%, an
or other relevant parameter sets as well). Our results suggest that
he differences in the absolute attack rates are greater for reactive
accination than for pre-pandemic vaccination.
If the primary response is lower than 50%, then our simula-
ions showed that the best strategy will depend on key parameters
f infection. We  then considered other parameters affecting the
ourse of an epidemic. For these results, we considered a vaccine
hat would be as good as the current seasonal vaccine, and used
he vaccine efﬁcacy values provided in Basta et al. (2008) and a pri-
ary response level of 30%. However, sensitivity analysis showed
hat our conclusions are not sensitive to these assumptions (Figs.
7–S10). In Fig. 6A, we considered different vaccination dates: the
ater vaccination occurs, the lower the threshold value R* becomes. 70%. We considered vaccination of 50% of the population with a single dose or 25%
S = 15%, VEI = 0%, and VEP = 24%), a medium-efﬁcacy vaccine (VES = 40%, VEI = 22.5%,
= 75%), and a high-efﬁcacy vaccine (VES = 66%, VEI = 45%, and VEP = 100%).
For example, if vaccination were to occur on day 45 after the begin-
ning of the epidemic, then R* = 1.7, but if vaccination occurred on
day 75, then R* = 1.4. Furthermore, the absolute difference between
the attack rates of the two-dose strategy and the one-dose strategy
is more important if vaccination occurs early, and it is attenuated as
vaccination gets delayed. If vaccination started on or after day 90,
this difference is less than 3% (Fig. S3). We  analyzed the inﬂuence of
the vaccine efﬁcacy kinetics after vaccination on the threshold R*.
As expected, concave vaccine efﬁcacy components yield smaller
attack rates than convex ones. In addition, the more concave the
vaccine efﬁcacy components are, the lower the threshold values of
R* are, but the difference both in the values of R* and the absolute
difference between the attack rates were minimal (Figs. 6B and S4).
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Fig. 4. Final attack rates for 50% coverage with one dose (solid lines) or 25% coverage with two doses (dashed lines) when vaccination occurs 45 days after the beginning
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onsidered: a low-efﬁcacy vaccine (VES = 15%, VEI = 0%, and VEP = 24%), a vaccine as 
accine (VES = 66%, VEI = 45%, and VEP = 100%).
e  investigated how population coverage would affect the thresh-
ld R* (Fig. 6C). Increasing the proportion of the population being
accinated had some effect in the threshold value R*. For exam-
le, when 20% of the population was vaccinated with a single dose,
* = 1.9, but this value decreased to 1.7 if 80% of the population was
accinated with one dose. In addition, for medium and high values
f R0, the absolute difference in the attack rates increased as pop-
lation coverage increased (Fig. S5). Finally, we analyzed the effect
f the values of the vaccine efﬁcacy components on the thresh-
ld R*, and found that the threshold R* decreases very little as the
accine becomes better (that is, if any of the vaccine efﬁcacy com-
onents increase, the threshold R* decreases, Fig. 6D). However,
accine efﬁcacy components had an interesting effect in the abso-
ute difference in the attack rates. At both ends (low vaccine efﬁcacy
r high vaccine efﬁcacy), both strategies yield similar differences
n the attack rates, with less than 5% absolute difference for all val-
es of R0. However, when vaccine efﬁcacy is moderate and R0 has
n intermediate value, the two-dose strategy would yield 5% less
ttack rate than the one-dose strategy (Fig. S6).
In contrast to our previous results, when the primary response
evel was set to 50% or higher, we found numerically that therimary response level = 40%. (D) Primary response level = 50%. Three vaccines were
ious as a seasonal vaccine (VES = 40%, VEI = 45%, and VEP = 75%), and a high-efﬁcacy
one-dose strategy always resulted in lower attack rates than the two
dose strategy in all the scenarios considered for reactive vaccination
(varying vaccination dates, vaccine efﬁcacy kinetics, vaccine efﬁ-
cacy values or vaccination coverage). This suggests that if the ﬁrst
dose of vaccine yields a strong immune response, then for reactive
vaccination, priming a larger proportion of the population may  be
a better use of resources than vaccinating half as many with the full
two doses (Fig. S11).
4. Discussion
We  used a mathematical model to determine the best use of
resources when vaccine supplies are constrained in the event of
an inﬂuenza A (H7N9) epidemic. Our results can also be used in
the event of an inﬂuenza A (H5N1) epidemic. Given that the cur-
rent vaccines being tested are supposed to be administered in
two doses, we examined the strategy of vaccinating a large num-
ber of people with a single dose versus vaccinating half as many
with the recommended full two  doses of vaccine. We  performed a
thorough analysis to investigate under which circumstances each
strategy yields lower attack rates. We  found that there is not a
L. Matrajt et al. / Epidemic
Fig. 5. Contour lines of the absolute difference between the attack rates of the two-
dose and one-dose strategies as a function of the primary response level and R0. Here,
we  considered vaccinating 50% of the population with a single dose of a seasonal
vaccine and vaccination on day 45 after the beginning of the epidemic or 25% of the
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niversal answer to this question, and that the best use of resources
epends most of all, on the protection obtained after the ﬁrst
ose of vaccine (the primary response level), on the timing of
he delivery of vaccine, and on the transmissibility of the virus
measured through R0). To a lesser extent, the optimal strategy
epends on the vaccine efﬁcacy components and on the shape of
he vaccine efﬁcacy components building up once an individual is
accinated.
If the vaccine-induced immunity after the ﬁrst dose is half as
ood as that of the full recommended dose (so the primary response
evel is 50%), then we found some surprising results: If the vaccine
s protective against susceptibility only, then our analytical results
howed that prepandemic vaccination should be done with the
ull recommended two doses of vaccine, as this would yield lower
ttack rates. However, if vaccination occurs after the epidemic has
tarted, then numerical results suggest that the best strategy would
e to vaccinate as many people as possible with a single dose. If in
ddition the vaccine reduces infectiousness or pathogenicity, then
umerical results suggest that the one-dose strategy would be bet-
er in both cases. If, on the other hand, the primary response level
s below 50%, then our results suggest that there is a threshold in
he values of R0, below which the two  − dosestrategy is better,
nd above it the one − dosestrategy yields lower attack rates. This
hreshold is dynamic, and it depends on when vaccine is admin-
stered, how good the vaccine is, the shape of the vaccine efﬁcacy
omponents after vaccination, and the vaccination coverage. Our
esults are in alignment with previous work (Riley et al., 2007;
ood et al., 2009).
Candidate vaccines against inﬂuenza A (H7N9) are currently in
linical trials (NIH, 2014), thus vaccine-induced immune responses
ave not been characterized yet. Our results highlight the impor-
ance of obtaining more information before taking any decision
bout the best use of resources. In particular, it is crucial to know
he level of protection obtained after a single dose, as this seems
o be a determining factor in deciding which strategy is better. In
his sense, better and more complete studies need to be performed
uring clinical trials, where in addition to evaluating the standards 13 (2015) 17–27 23
vaccine safety and immunogenicity, other key parameters of vac-
cine efﬁcacy and its interactions with the immune system could be
measured at several time points.
A number of candidate two-dose inﬂuenza H5N1 vaccines have
gone through phase I and II safety and immunogenicity trials
(Bresson et al., 2006; Lin et al., 2006; Leroux-Roels et al., 2007;
Treanor et al., 2006). These vaccine trials have included arms at dif-
ferent antigen doses ranging from 3.75 to 40 g, with and without
adjuvants, and with both homologous and heterologous testing.
The main measures of immunogenicity have been based on serum
hemagglutination inhibition (HAI) titers and neutralization anti-
body titers. Results varied considerably among the trials, but on
average, for all doses tested, the use of vaccine with adjuvant
resulted in geometric mean titers that were roughly twice as high
just after the second dose, compared to just after the ﬁrst dose;
the same was  true for seroconversion proportions (Leroux-Roels
et al., 2007). Although it is currently unknown exactly how these
immune measures predict vaccine efﬁcacy (VE), the HAI titers have
been shown to be a good correlate of protection for infection and
inﬂuenza-like illness for both natural and vaccine induced immu-
nity to seasonal inﬂuenza (Coudeville et al., 2010). This would imply
that the primary response level for these vaccines could be in the
region of 50%, further supporting vaccination with a single dose
to as many people as possible. However, additional work needs to
be done in this area to determine more precise estimates of both
the primary response level and VE parameters, VES, VEP and VEI,
from immunogenicity data. Furthermore, these conclusions were
obtained for inﬂuenza H5N1, and extrapolation might be inade-
quate. Equivalent studies would be needed speciﬁcally aimed at
inﬂuenza H7N9.
Our results have some limitations. Our model is intentionally
simple to avoid possible confounders and to allow us to derive
mathematical thresholds and general conclusions. The aim of the
present work was  to investigate the importance and impact of key
parameters in determining the best use of vaccine under a one
versus two-dose scenario. Models including age-groups or high-
risk groups are more realistic, but such models introduce more
variables and different questions to consider: how to prioritize vac-
cine among high and low transmission groups (e.g give one dose
to adults and full dosage to children), how to prioritize vaccine
among high and low risk groups, trade-offs between transmission-
reducing versus mitigation strategies in the resulting attack rates,
how to model morbidity and mortality in different age-groups,
etc. These questions are highly important and are the subject of
future research. We  assumed that vaccine efﬁcacies would induce
the same protection across age-groups. Evidence based on seasonal
inﬂuenza vaccines suggest, however, that this might not be the case,
with the elderly obtaining lower protection (Jefferson et al., 2010;
Osterholm et al., 2012). We based our decisions on illness attack
rates, but other measures, like mortality or morbidity, could be
useful in preparing for a pandemic. In reality, the optimal use of
vaccine probably involves vaccinating high-risk groups with two
doses and low-risk ones with a single dose. We assumed that a vac-
cine for either H5N1 or H7N9 inﬂuenza strains would require two
doses (indeed, all vaccines ongoing clinical trials currently have a
two-dose schedule). This assumption is based on immune respon-
siveness for seasonal vaccines, and we actually do not know if the
established correlations between immune responsiveness and vac-
cine efﬁcacy for seasonal vaccines can be translated for pandemic
or zoonotic vaccines.
With new cases of inﬂuenza A (H7N9) arising, it is important for
public health ofﬁcials to have a clear vaccination policy in place as
part of a prepandemic preparedness plan. The methods proposed
here could help guiding this policy. As a shortage of vaccine is likely
to occur, it is important to maximize the beneﬁts that the available
vaccine can give to the entire population.
24 L. Matrajt et al. / Epidemics 13 (2015) 17–27
Fig. 6. Final attack rates for one dose (solid lines) and two doses (dashed lines) varying (A) vaccination dates; (B) the kinetics of the vaccine efﬁcacies; (C) vaccination
coverage; (D) vaccine efﬁcacy values. For (D), four different vaccines were considered: a low-efﬁcacy vaccine (VES = 15%, VEI = 0%, and VEP = 24%), a medium-efﬁcacy vaccine
( (VES =
V
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fVES = 40%, VEI = 22.5%, and VEP = 62%), a vaccine as efﬁcacious as a seasonal vaccine 
EP = 100%). The primary response level was set to 30%.
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Appendix A.
A.1. Model
We  use a differential equations model to simulate an inﬂuenza
epidemic. We  partitioned the population into those who are sus-
ceptible unvaccinated or vaccinated (Si, i = 0, 1 for unvaccinated and
vaccinated respectively), infectious Iij with vaccinated status i and
symptomatic status j, and recovered Recij with vaccinated status i
idemic
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nd symptomatic status j (j = 0 for asymptomatic and j = 1 for symp-
omatic). A fraction k of those infected will develop symptoms,
hile the rest become asymptomatic. Infected asymptomatic peo-
le have their infectiousness reduced by a factor m (m ∈ [0, 1]). All
he infected people recover at the same rate,  . The model consists
f a system of eight ordinary differential equations:
Unvaccinated Vaccinated
dS0
dt
= −S0
dS1
dt
= −S1
dI00
dt
= (1 − k)S0 − I00
dI10
dt
= (1 − k )S1 − I10
dI01
dt
= kS0 − I01
dI11
dt
= k S1 − I11
dRec00
dt
= I00
dRec10
dt
= I10
dRec01
dt
= I01
dRec11
dt
= I11
ubject to the conditions
(t) = cp
N
(mI00 + I01 + mI10 + I11),
ith c being the contact rate and p is the probability of infection. The
alue of cp was  varied to obtain different values of R0. Vaccination
s modeled with a leaky vaccine with three different components,
ES = 1 − , VEI = 1 − , and VEP = 1 −  (Table 1).
We constructed a one-parameter family of functions to model
accine efﬁcacy components increasing over time,
 (t) =
{
VE ∗ r1(t/14)exp(s1) for 0 ≤ t ≤ 14
VE ∗ r1 for t ≥ 14
(1)
or one dose of vaccine and
 (t) =
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
VE ∗ r1(t/14)exp(s1) for 0 ≤ t ≤ 14
VE ∗ r1 for 14 ≤ t ≤ 21
VE ∗ (r1 + (1 − r1)(t − 21/7)exp(s2)) for 21 ≤ t ≤ 28
VE for t ≥ 28
(2)
or two doses of vaccine. VE is the vaccine efﬁcacy, s1 and s2 are free
arameters that allow us to vary the convexity of the function f(t)
si = 0 results in a linear function), and r1 is the primary response
evel. For all the results, except those where the shape of the vaccine
fﬁcacies was studied, we assumed that vaccine efﬁcacies develop
inearly in time, and assumed that the primary response level would
e the same for all three efﬁcacies.
.2. Reproduction number and ﬁnal size relation: the general case
Results shown below concern pre-pandemic vaccination only.
The basic reproduction number R0 in the absence of vaccination
or this model has been previously shown (Matrajt and Longini,
012) to be given by
0 = ((1 − k)m + k)r0 (3)
here r0 = cp/ . If a fraction v of the population is vaccinated, then
he effective reproduction number Rv is
v = r0
{
(1 − v)((1 − k)m + k) + v((1 − k)m + k)
}
. (4)Similarly to Arino et al. (2006), we derived the ﬁnal size rela-
ions for this model. Here, we obtain two balance equations, one
or the unvaccinated and one for the vaccinated populations. Let pu
e the fraction of the unvaccinated who got infected (among theses 13 (2015) 17–27 25
a fraction k are symptomatic), and pv be the fraction among the vac-
cinated who  got infected (and a fraction  k among them become
symptomatic).
1 − pu = exp [−r0 ((1 − v)pu((1 − k)m + k)
+ vpv((1 − k)m + k)
)]
, (5)
1 − pv = exp
[
−r0 ((1 − v)pu((1 − k)m + k)
+ vpv((1 − k)m + k)
)]
. (6)
From this we  see that (1 − pv) = (1 − pu) as expected.
A.3. Vaccine reducing susceptibility only
Suppose now that vaccination produces no reduction in infec-
tivity or probability of symptomatic inﬂuenza so that VEI = VEP = 0.
This corresponds to  =  = 1. Further, suppose that the ﬁrst dose
reduces susceptibility by a factor e1 (so the relative susceptibility
is (1 − e1) and the second dose reduces susceptibility even further
by a factor e2. Then, the vaccine efﬁcacy for susceptibility VES (after
two doses) is given by
VES = 1 −  = 1 − (1 − e1)(1 − e2) = e1 + e2 − e1e2 (7)
with the primary response level r1 given by:
r1 =
e1
e1 + e2 − e1e2
. (8)
Note that here the primary response level is expressed as a fraction
rather than a percentage.
Assume that a fraction v of the population is vaccinated with
one dose. The reproduction number R1 is given by
R1 = R0(1 − e1v), (9)
and the balance Eqs. (5) and (6) become
1 − pu = exp [−r0((1 − k)m + k) ((1 − v)pu + vpv)] ,  (10)
1 − pv = exp [−(1 − e1)r0((1 − k)m + k) ((1 − v)pu + vpv)] . (11)
If we take the weighted average p1 = (1 − v)pu + vpv of the two
equations we  get an equation for the overall fraction infected p1:
p1 = 1 − (1 − v)e−R0p1 − ve−R0(1−e1)p1 . (12)
Analogously, when a fraction v/2 is vaccinated with two doses
with a vaccine efﬁcacy for susceptibility VES = 1 − (1 − e1)(1 − e2)
the reproduction number R2 is given by
R2 = R0
(
1 − ( e1 + e2 − e1e2
2
v)
)
, (13)
and the ﬁnal size relation becomes
p2 = 1 − (1 −
v
2
)e−R0p2 − v
2
e−R0(1−e1)(1−e2)p2
= 1 − e−R0p2 + v
2
e−R0p2 − v
2
e−R0(1−e1)(1−e2)p2
= 1 − (1 − v)e−R0p2 − v
2
(
e−R0p2 + e−R0(1−e1)(1−e2)p2
)
.
(14)
Theorem 1. If a vaccine reduces susceptibility only (so that VES > 0
but VEI = 0 = VEP), then there is a value r∗1 > 0.5, such that p2 < p1 if
and only if r1 < r∗1 (and p2 = p1 if and only if r1 = r∗1).
Proof. First, when r1 = 0.5, we  have that (1 − e1)(1 − e2) = 1 −2e1
and the expressions (12) and (14) become
p1 = 1 − (1 − v)e−R0p1 − ve−R0(1−e1)p1 (15)
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Table 1
Parameter values.
Parameter Description Value Reference
 Recovery rate 0.25 Longini et al. (2004)
k Fraction of symptomatic 2/3 Longini et al. (2004)
m Reduction of infectiousness for asymptomatics 0.5 Longini et al. (2004)
cp Contact rate, probability of transmission – Calculated to obtain the desired R0
v Fraction vaccinated – Varied throughout text
VES = 1 −  Vaccine efﬁcacy for susceptibility for seasonal inﬂuenza 40 Basta et al. (2008)
VEI = 1 −  Vaccine efﬁcacy for infectiousness for seasonal inﬂuenza 45 Basta et al. (2008)
VEP = 1 − Vaccine efﬁcacy for pathogenicity for seasonal inﬂuenza 75 Basta et al. (2008)
N Total population 1,000,000 Assumption
Initially infected fraction of the population 1/1,000,000 Assumption
p
C
s
T
e
f
e
T
r
d
t
A
V
r
a
d
l
i
b
(
w
1
I
i
1
T
t
v
t
r
r2 = 1 − (1 − v)e−R0p2 −
v
2
(e−R0p2 + e−R0(1−2e1)p2 ) . (16)
onsider the function f(x) = e−R0(1−x)p1 . If x1 ≤ x2, then f(x1) ≤ f(x2),
o that
e−R0(1−x1)p1 ≤ e−R0(1−x2)p1 and
1 − (1 − v)e−R0p1 − ve−R0(1−x1)p1 ≥
1 − (1 − v)e−R0p1 − ve−R0(1−x2)p1 .
his implies that p1 is monotonically decreasing in e1 (the more
ffective vaccine the fewer get infected) and hence in r1. Now, the
unction f(x) is convex, so we have
−R0(1−e1)p1 ≤ 1
2
(e−R0(1−2e1)p1 + e−R0p1 ) .
his implies that p2 ≤ p1 if r1 ≤ 0.5, and it follows that there exists
∗
1, such that r
∗
1 > 0.5, for which p2 = p1.
Note: the value of this threshold depends on R0 as well, so it
epends indirectly on other parameters of the model other than
he primary response level. 
.4. Vaccine reducing infectiousness only
Assume now a vaccine reduces infectiousness only (so that
EI > 0 but VES = 0 = VEP). Suppose, as before, that a single dose
educes infectivity by a factor e1 and a second dose reduces it by an
dditional factor e2. The relative infectivity is hence (1 − e1) for one
ose and (1 − e1)(1 − e2) for two doses, and the primary response
evel (for infectivity) equals r1 = e1/(e1 + e2 − e1e2).
Since the vaccine has no effect on susceptibility, the fraction
nfected among the vaccinated and unvaccinated populations will
e identical. We  hence obtain a single balance equation from Eqs.
5) and (6) for the fraction p1 of the population getting infected
hen a fraction v of the population is vaccinated with a single dose,
 − p1 = e−R0(1−e1v)p1 . (17)
f instead a fraction v/2 is vaccinated with 2 doses, the ﬁnal fraction
nfected, now denoted p2, solves the equation
 − p2 = e−R0(1−(e1+e2−e1e2)v/2)p2 . (18)
heorem 2. Assume a vaccine that reduces infectiousness only (so
hat VEI > 0 but VES = 0 = VEP). Vaccinating with two doses a fraction
/2 of the population yields lower attack rates than vaccinating a frac-
ion v of the population with a single dose if and only if the primary
esponse level is less than 50%. Mathematically: p2 ≤ p1 if and only if
1 ≤ 0.5.Proof.
p2 ≤ p1 iff − R0(1 −
(e1 + e2 − e1e2)v
2
) ≤ −R0(1 − e1v)
iff
e1
e1 + e2 − e1e2
≤ 1
2
.
Note that here the inequality depends only on the primary
response level, hence this result is independent of all the other
parameters of the model. 
A.5. Vaccine reducing pathogenicity only
Suppose now instead that the vaccine has no effect on suscepti-
bility, nor on infectivity for symptomatic and asymptomatic cases,
but that the only effect is that it increases the chance of having no
symptoms (i.e. becoming asymptomatic). As before we let e1 and e2
respectively be the reduction factors for one dose and an additional
vaccine dose.
More precisely, without vaccination an infected person becomes
symptomatic with probability k. If vaccinated with one dose this
probability then becomes (1 − e1)k and after 2 doses it becomes
(1 − e1)(1 − e2)k. As in the previous case there is no reduction in
susceptibility, and the equation for the fraction p1 of the population
getting infected when a fraction v of the population is vaccinated
with a single dose is given by
1 − p1 = exp [−r0 ((1 − v)(k + (1 − k)m) + v((1 − e1)k
+(1 − (1 − e1)k)m))p1] . (19)
If instead a fraction v/2 of the population is vaccinated with 2 doses,
the fraction p2 who  got infected is given by
1 − p2 = exp
[
−r0
(
(1 − v/2)(k + (1 − k)m) + (v/2)((1 − e1)
×(1 − e2)k + (1 − (1 − e1)(1 − e2)k)m))p2] . (20)
Theorem 3. Assume a vaccine that reduces pathogenicity only (so
that VEP > 0 but VES = 0 = VEI). Vaccinating with two doses a fraction
v/2 of the population yields lower attack rates than vaccinating a frac-
tion v of the population with a single dose if and only if the primary
response level is less than 50%. Mathematically: p2 ≤ p1 if and only if
r1 ≤ 0.5.
idemic
P
p1 ⇔
)k)m
)m ≤
1
2
(k 
me1
2
1e2)
e1
2 − e1
1
2

A
t
0
R
A
B
B
C
C
C
C
C
H
H
J
LL. Matrajt et al. / Ep
roof.
p2 ≤ 
(1 − v
2
)(k + (1 − k)m) + v
2
((1 − e1)(1 − e2)k + (1 − (1 − e1)(1 − e2
(1 − v
2
)(k + (1 − k)m) + v
2
((1 − e1)(1 − e2)k + (1 − (1 − e1)(1 − e2)k
1
2
((1 − e1)(1 − e2)k + (1 − (1 − e1)(1 − e2)k)m) ≤ −
k
2
− ke2
2
− ke1
2
+ m
2
+ ke1e2
2
− km
2
− kme2
2
− kme1
2
+ k
−1
2
(1 − m)(e1 + e2 − e
1
2
≥
e1 + e
r1 ≤
ppendix B. Supplementary Data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.epidem.2015.06.
01
eferences
rino, J., Brauer, F., van den Driessche, P., Watmough, J., Wu,  J., 2006. Simple models
for  containment of a pandemic. J. R. Soc. Interface 3 (8), 453–457.
asta, N., Halloran, M.E., Matrajt, L., Longini, I.M., 2008. Estimating inﬂuenza vaccine
efﬁcacy from challenge and community-based study data. Am.  J. Epidemiol. 168
(12), 1343–1352.
resson, J.L., Perronne, C., Launay, O., Gerdil, C., Saville, M.,  Wood, J., et al.,
2006. Safety and immunogenicity of an inactivated split-virion inﬂuenza
A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367
(9523), 1657–1664.
han, M.C., Chan, R.W., Chan, L.L., Mok, C.K., Hui, K.P., Fong, J.H., et al., 2013.
Tropism and innate host responses of a novel avian inﬂuenza A H7N9 virus:
an  analysis of ex-vivo and in-vitro cultures of the human respiratory tract.
Lancet Respir. Med. 7, Available from: http://linkinghub.elsevier.com/retrieve/
pii/S2213260013701383
IDRAP, 2013. Federal Ofﬁcials Weigh H7N9 Vaccine Options. http://www.cidrap.
umn.edu/news-perspective/2013/06/federal-ofﬁcials-weigh-h7n9-vaccine-
options
IDRAP, 2014a. Avian Flu Scan for Nov 17, 2014. http://www.cidrap.umn.edu/news-
perspective/2014/11/avian-ﬂu-scan-nov-17-2014
IDRAP, 2014b. Flu Scan for Apr 07, 2014. http://www.cidrap.umn.edu/news-
perspective/2014/04/ﬂu-scan-apr-07-2014
oudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., Ecochard, R., 2010.
Relationship between haemagglutination-inhibiting antibody titres and clini-
cal  protection against inﬂuenza: development and application of a Bayesian
random-effects model. BMC Med. Res. Methodol. 10 (1), 18, Available from:
http://www.biomedcentral.com/1471-2288/10/18
alloran, M.E., Struchiner, C.J., Spielman, A., 1989. Modeling malaria vaccines. II:
Population effects of stage-speciﬁc malaria vaccines dependent on natural
boosting. Math. Biosci. 94 (1), 115–149.
alloran, M.E., Struchiner, C.J., Longini, I.M., 1997. Study designs for evaluating dif-
ferent efﬁcacy and effectiveness aspects of vaccines. Am.  J. Epidemiol. 146 (10),
789–803.
efferson, T., Di Pietrantonj, C., Al-Ansary, L.A., Ferroni, E., Thorning, S., Thomas, R.E.,
2010. Vaccines for preventing inﬂuenza in the elderly. Cochrane Database Syst.
Rev. (2), CD004876.
eroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M.,  Clement, F., Hons, E.,
et  al., 2007. Antigen sparing and cross-reactive immunity with an adjuvanted
rH5N1 prototype pandemic inﬂuenza vaccine: a randomised controlled trial.s 13 (2015) 17–27 27
) ≤ (1 − v)(k + (1 − k)m) + v((1 − e1)k + (1 − (1 − e1)k)m) ⇔
 (1 − v
2
− v
2
)(k + (1 − k)m) + v((1 − e1)k + (1 − (1 − e1)k)m ⇔
+ (1 − k)m) + m((1 − e1)k + (1 − (1 − e1)k) ⇔
e2 ≤ − k
2
− m
2
+ km
2
+ k − ke1 + m − km + kme1 ⇔
 ≤ −e1(1 − m)  ⇔
e2
⇔
Lancet 370 (9587), 580–589, Available from: http://www.sciencedirect.com/
science/article/pii/S0140673607612975
Lin, J., Zhang, J., Dong, X., Fang, H.,  Chen, J., Su, N., et al., 2006. Safety
and immunogenicity of an inactivated adjuvanted whole-virion inﬂuenza A
(H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 (9540),
991–997.
Linster, M.,  van Boheemen, S., de Graaf, M.,  Schrauwen, E.J.A., Lexmond, P., Mänz, B.,
et  al., 2014. Identiﬁcation, characterization, and natural selection of mutations
driving airborne transmission of A/H5N1 virus. Cell 157 (2), 329–339, Available
from: http://www.cell.com/cell/abstract/S0092-8674(14)00281-5
Longini, I.M.J., Halloran, M.E., Nizam, A., Yang, Y., 2004. Containing pandemic
inﬂuenza with antiviral agents. Am.  J. Epidemiol. 159 (7), 623–633, Available
from: http://aje.oxfordjournals.org/cgi/content/abstract/159/7/623
Matrajt, L., Longini Jr., I.M., 2012. Critical immune and vaccination thresh-
olds for determining multiple inﬂuenza epidemic waves. Epidemics 4
(1), 22–32, Available from: http://www.sciencedirect.com/science/article/pii/
S1755436511000570
NIH, 2013. NIH Begins Testing H7N9 Avian Inﬂuenza Vaccine Candidate. http://
www.nih.gov/news/health/sep2013/niaid-18.htm (last accessed October 2014).
Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., 2012. Efﬁcacy and effective-
ness of inﬂuenza vaccines: a systematic review and meta-analysis. Lancet Infect
Dis. 12 (1), 36–44.
Osterholm, M.T., Ballering, K.S., Kelley, N.S., 2013. Major challenges in providing an
effective and timely pandemic vaccine for inﬂuenza A(H7N9). JAMA 309 (24),
2557–2558, http://dx.doi.org/10.1001/jama.2013.6589
Riley, S., Wu,  J.T., Leung, G.M., 2007. Optimizing the dose of pre-pandemic inﬂuenza
vaccines to reduce the infection attack rate. PLoS Med. 4 (6), e218.
Treanor, J.J., Campbell, J.D., Zangwill, K.M., Rowe, T., Wolff, M.,  2006. Safety and
immunogenicity of an inactivated subvirion inﬂuenza A (H5N1) vaccine. N. Engl.
J.  Med. 354 (13), 1343–1351.
Uyeki, T.M., Cox, N.J., 2013. Global concerns regarding novel inﬂuenza A (H7N9)
virus infections. N. Engl. J. Med. 368 (20), 1862–1864, PMID: 23577629. Available
from: http://www.nejm.org/doi/full/10.1056/NEJMp1304661
WHO, 2013. Summary of Status of Development and Availability of Avian Inﬂuenza
A(H7N9) Candidate Vaccine Viruses. http://www.who.int/inﬂuenza/vaccines/
virus/candidates reagents/summary a h7n9 cvv 20130926.pdf
WHO, 2013. Human Infection with Inﬂuenza A(H7N9) Virus in China. http://www.
who.int/csr/don/2013 04 01/en/index.html
WHO, 2014. Cumulative Number of Conﬁrmed Human Cases for Avian Inﬂuenza
A(H5N1) Reported to WHO, 2003–2014. http://www.who.int/inﬂuenza/human
animal interface/EN GIP 20140124CumulativeNumberH5N1cases.pdf?ua=1
Wood, J., McCaw, J., Becker, N., Nolan, T., Macintyre, R.M., Optimal Dosing, 2009.
Dynamic Distribution of Vaccines in an Inﬂuenza Pandemic. Am.  J. Epidemiol.
169 (12), 1517–1524.
Xu, L., Bao, L., Deng, W.,  Dong, L., Zhu, H., Chen, T., et al., 2013. The novel avian-
origin human A (H7N9) inﬂuenza virus could be transmitted between ferrets via
respiratory droplets. J. Infect. Dis. 08, Available from: http://jid.oxfordjournals.
org/content/early/2013/08/29/infdis.jit474.abstract
